Synergo for non-muscle-invasive bladder cancer: Medical technology consultation document
DRAFT guidance notes there is not enough good-quality evidence to support case for routine adoption of Synergo for high-risk non-muscle-invasive bladder cancer that has not responded to/has recurred after BCG treatment, or when people cannot or do not want to have BCG treatment.
Source:
National Institute for Health and Care Excellence
SPS commentary:
Synergo treats non-muscle-invasive bladder cancer using a radiofrequency-induced thermo-chemotherapeutic effect. It heats the superficial layers of the bladder wall using controlled radiofrequency radiation and flushes the bladder with a chemotherapy drug at the same time (thermochemotherapy). The drug solution is continuously pumped out of the bladder, cooled, and recirculated to prevent overheating. A miniature antenna in the catheter directs radiofrequency radiation at the bladder wall tissue, at a depth that does not generate heat on the outer surface of the bladder, to avoid injuring surrounding organs.